GlassScriptPhysician profile
Robert C Gifford
NPI 1700104320
$280.66
in general payments reported to CMS, 2019-2025
11 companies · $27.48 in 2025
The $27.48 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.38 · 2022: $79.84 · 2023: $67.72 · 2024: $81.24 · 2025: $27.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medshape, INC. | $79.84 | 2022 | |
| Fidia Pharma USA INC. | $35.97 | 2024 | Hyalgan, Triluron, Hymovis |
| Globus Medical, INC. | $28.77 | 2024 | Ankle Fracture System |
| Si-Bone, INC. | $27.48 | 2025 | |
| Integra Lifesciences Corporation | $20.69 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Curonix LLC | $16.50 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Sanofi-Aventis U.S. LLC | $16.48 | 2023 | |
| Nevro Corp. | $16.31 | 2023 | Senza |
| Kci USA, INC. | $14.24 | 2023 | Activ.A.C., Snap, Promogran Prisma |
| Linvatec Corporation | $13.48 | 2019 | |
| Arthrosurface Incorporated | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gifford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.